These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 30464200)
1. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200 [TBL] [Abstract][Full Text] [Related]
2. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. Gadaleta RM; Garcia-Irigoyen O; Cariello M; Scialpi N; Peres C; Vetrano S; Fiorino G; Danese S; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A EBioMedicine; 2020 Apr; 54():102719. PubMed ID: 32259714 [TBL] [Abstract][Full Text] [Related]
3. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. Piglionica M; Cariello M; Moschetta A Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181 [TBL] [Abstract][Full Text] [Related]
4. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism. Cariello M; Piglionica M; Gadaleta RM; Moschetta A Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830 [TBL] [Abstract][Full Text] [Related]
5. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4 Cariello M; Peres C; Zerlotin R; Porru E; Sabbà C; Roda A; Moschetta A Sci Rep; 2017 Sep; 7(1):11203. PubMed ID: 28894223 [TBL] [Abstract][Full Text] [Related]
6. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755 [TBL] [Abstract][Full Text] [Related]
7. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587 [TBL] [Abstract][Full Text] [Related]
8. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724 [TBL] [Abstract][Full Text] [Related]
9. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251 [TBL] [Abstract][Full Text] [Related]
11. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Al-Khaifi A; Rudling M; Angelin B Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896 [TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184 [TBL] [Abstract][Full Text] [Related]
13. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428 [TBL] [Abstract][Full Text] [Related]
14. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580 [TBL] [Abstract][Full Text] [Related]
15. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907 [TBL] [Abstract][Full Text] [Related]
16. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340 [TBL] [Abstract][Full Text] [Related]
17. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. Hu X; Bonde Y; Eggertsen G; Rudling M J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394 [TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979 [TBL] [Abstract][Full Text] [Related]
19. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho. Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219 [TBL] [Abstract][Full Text] [Related]
20. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]